176 related articles for article (PubMed ID: 10685537)
1. The significance of delayed suppression using buserelin acetate and recombinant follicle-stimulating hormone in a long protocol in vitro fertilization program.
Ravhon A; Aurell R; Lawrie H; Margara R; Winston RM
Fertil Steril; 2000 Feb; 73(2):325-9. PubMed ID: 10685537
[TBL] [Abstract][Full Text] [Related]
2. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates.
Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
Fertil Steril; 1998 Dec; 70(6):1063-9. PubMed ID: 9848296
[TBL] [Abstract][Full Text] [Related]
3. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
[TBL] [Abstract][Full Text] [Related]
4. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
Hohmann FP; Macklon NS; Fauser BC
J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
[TBL] [Abstract][Full Text] [Related]
5. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.
Borm G; Mannaerts B
Hum Reprod; 2000 Jul; 15(7):1490-8. PubMed ID: 10875855
[TBL] [Abstract][Full Text] [Related]
6. Dynamic assays of inhibin B and oestradiol following buserelin acetate administration as predictors of ovarian response in IVF.
Ravhon A; Lavery S; Michael S; Donaldson M; Margara R; Trew G; Winston R
Hum Reprod; 2000 Nov; 15(11):2297-301. PubMed ID: 11056122
[TBL] [Abstract][Full Text] [Related]
7. The initial flare-up induced by gonadotropin releasing hormone agonist may serve as a predictor of ovarian response in the current IVF-ET treatment cycle in normogonadotropic women aged 40-48 years.
Avrech OM; Royburt M; Sabah G; Zukerman Z; Pinkas H; Amit S; Ovadia J; Fisch B
J Assist Reprod Genet; 1996 May; 13(5):395-400. PubMed ID: 8739055
[TBL] [Abstract][Full Text] [Related]
8. Basal 17beta-estradiol did not correlate with ovarian response and in vitro fertilization treatment outcome.
Phophong P; Ranieri DM; Khadum I; Meo F; Serhal P
Fertil Steril; 2000 Dec; 74(6):1133-6. PubMed ID: 11119739
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection.
Takeuchi S; Minoura H; Shibahara T; Tsuiki Y; Noritaka F; Toyoda N
Fertil Steril; 2001 Sep; 76(3):532-7. PubMed ID: 11532477
[TBL] [Abstract][Full Text] [Related]
10. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
Vuong TN; Phung HT; Ho MT
Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
[TBL] [Abstract][Full Text] [Related]
11. Addition of low-dose hCG to rFSH during ovarian stimulation for IVF/ICSI: is it beneficial?
Partsinevelos GA; Antonakopoulos N; Kallianidis K; Drakakis P; Anagnostou E; Bletsa R; Loutradis D
Clin Exp Obstet Gynecol; 2016; 43(6):818-825. PubMed ID: 29944230
[TBL] [Abstract][Full Text] [Related]
12. Placental protein 14 concentrations in circulation related to hormonal parameters and reproductive outcome in women undergoing IVF/ICSI.
Westergaard LG; Yding Andersen C; Erb K; Laursen SB; Rasmussen PE; Rex S; Teisner B
Reprod Biomed Online; 2004 Jan; 8(1):91-8. PubMed ID: 14759294
[TBL] [Abstract][Full Text] [Related]
13. Comparison of stimulation with clomiphene citrate in combination with recombinant follicle-stimulating hormone and recombinant luteinizing hormone to stimulation with a gonadotropin-releasing hormone agonist protocol: a prospective, randomized study.
Weigert M; Krischker U; Pöhl M; Poschalko G; Kindermann C; Feichtinger W
Fertil Steril; 2002 Jul; 78(1):34-9. PubMed ID: 12095487
[TBL] [Abstract][Full Text] [Related]
14. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
15. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial.
Cheung LP; Lam PM; Lok IH; Chiu TT; Yeung SY; Tjer CC; Haines CJ
Hum Reprod; 2005 Mar; 20(3):616-21. PubMed ID: 15608037
[TBL] [Abstract][Full Text] [Related]
16. A prospective, randomized controlled trial comparing the efficacy of recombinant follicle-stimulating hormone in three different in vitro fertilization protocols.
Ravhon A; Lawrie H; Ellenbogen A; Lavery S; Trew G; Winston R
Fertil Steril; 2000 May; 73(5):908-12. PubMed ID: 10785215
[TBL] [Abstract][Full Text] [Related]
17. A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment.
Yong PY; Brett S; Baird DT; Thong KJ
Fertil Steril; 2003 Feb; 79(2):308-15. PubMed ID: 12568839
[TBL] [Abstract][Full Text] [Related]
18. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
[TBL] [Abstract][Full Text] [Related]
19. Effects of functional ovarian cysts detected on the 7th day of gonadotropin-releasing hormone analog administration on the outcome of IVF treatment.
Biljan MM; Lapensée L; Mahutte NG; Bissonnette F; Hemmings R; Tan SL
Fertil Steril; 2000 Nov; 74(5):941-5. PubMed ID: 11056237
[TBL] [Abstract][Full Text] [Related]
20. Effects of low day 3 luteinizing hormone levels on in vitro fertilization treatment outcome.
Noci I; Maggi M; Fuzzi B; Biagiotti R; Ricci F; Marchionni M
Gynecol Endocrinol; 2000 Oct; 14(5):321-6. PubMed ID: 11109971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
